Purpose: To evaluate the effect of mitomycin-C (MMC) on the success of external (Ex-DCR) or endoscopic dacryocystorhinostomy (En-DCR). Method: A systematic review of randomized clinical trials of Ex-or En-DCR with and without the use of MMC to treat primary acquired nasolacrimal duct obstruction (NLDO) was done. Two authors independently searched six databases from 1990 to 2019, using the terms ''dacryocystorhinostomy'' and ''mitomycin-C.'' Statistical and meta-analyses were performed using RevMan 5.3 software. Results: Twenty-seven studies involving 2158 surgeries were included in this systematic review. The Ex-DCR group comprised 14 studies [odds ratio (OR): 2.74; 95% confidence intervals (CI) 1.54-4.87; I 2 = 30%], while the En-DCR group 13 studies (OR: 1.69; 95% CI 1.21-2.37; I 2 = 0%). The use of MMC slightly increased the success rate of Ex-or En-DCR (OR: 2.1; 95% CI 1.52-2.9; I 2 = 14%). Conclusion: The intraoperative use of MMC is safe and slightly improves the success rate of Exor En-DCR. However, the evidence was very weak.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.